Zoledronic acid use in cancer patients

Cancer

Volumn 117, Issue 1, 2011, Pages 11-23

  Coleman, Robert ^a   Cook, Richard ^b   Hirsh, Vera ^c   Major, Pierre ^d   Lipton, Allan ^e  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF WATERLOO   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

adjuvant setting; bisphosphonate; bone metastases; cancer; survival; zoledronic acid

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; CAPECITABINE; CELECOXIB; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; DOXYCYCLINE; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GOSERELIN; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; OCTREOTIDE; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; TAMOXIFEN; THALIDOMIDE; VASCULOTROPIN; ZOLEDRONIC ACID;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE PAIN; BONE REMODELING; BONE TUMOR; BREAST CANCER; BREAST TUMOR; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RECURRENCE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG DOSE REDUCTION; GAMMA DELTA T LYMPHOCYTE; HUMAN; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SINGLE DRUG DOSE; SPINAL CORD COMPRESSION; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; NEOPLASMS; OSTEOLYSIS;

EID: 78650708531     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25529     Document Type: Article

References (103)

1. Coleman RE,. Bisphosphonates: clinical experience. Oncologist. 2004; 9 (suppl 4): 14-27.
2. Coleman RE,. Skeletal complications of malignancy. Cancer. 1997; 80 (suppl): 1588-1594.
3. Lipton A,. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol. 2004; 2: 205-213; discussion follows.
4. Saad F,. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev. 2008; 34: 183-192.
5. Patel N, Adatia R, Mellemgaard A, Jack R, Moller H,. Variation in the use of chemotherapy in lung cancer. Br J Cancer. 2007; 96: 886-890.
6. Major P,. Optimal management of metastatic bone disease. Eur J Oncol Nurs. 2007; 11 (suppl 2): S32-S37.
7. Kretzschmar A, Wiege T, Al-Batran SE, et al. Rapid and sustained influence of intravenous zoledronic acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. Support Cancer Ther. 2007; 4: 203-210.
8. Lipton A, Zheng M, Seaman J,. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003; 98: 962-969.
9. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98: 1735-1744.
10. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100: 2613-2621.
11. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96: 879-882. (Pubitemid 38807610)
12. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer. 2005; 92: 1869-1876.
13. Guise TA,. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev. 2008; 34 (suppl 1): S19-S24.
14. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360: 679-691.
15. Frassoldati A, Brufsky A, Bundred N, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24-month integrated follow-up of the Z-FAST and ZO-FAST trials [poster]. Poster presented at: 33rd Congress of the European Society for Medical Oncology; September 12-16, 2008; Stockholm, Sweden. Abstract 185 PD.
16. Winter MC, Thorpe HC, Burkinshaw R, Beevers SJ, Coleman RE,. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response - exploratory evidence for direct anti-tumor activity in breast cancer [poster]. Poster presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, Texas. Abstract 5101.
17. Winter MC, Holen I, Coleman RE,. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008; 34: 453-475.
18. Green JR,. Preclinical pharmacology of zoledronic acid. Semin Oncol. 2002; 29 (suppl 21): 3-11.
19. Mundy GR,. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2: 584-593.
20. Coxon JP, Oades GM, Kirby RS, Colston KW,. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 2004; 94: 164-170.
21. Kobune M, Chiba H, Kato J, et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther. 2007; 6: 1774-1784.
22. Duivenvoorden WC, Vukmirovic-Popovic S, Kalina M, Seidlitz E, Singh G,. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. Br J Cancer. 2007; 96: 1526-1531.
23. Hiraga T, Ueda A, Tamura D, et al. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer. 2003; 106: 973-979.
24. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI,. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001; 84: 1126-1134.
25. Melisi D, Caputo R, Damiano V, et al. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer. 2005; 12: 1051-1058.
26. Neville-Webbe HL, Evans CA, Coleman RE, Holen I,. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 2006; 27: 92-103.
27. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I,. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer. 2005; 113: 364-371.
28. Ottewell PD, Deux B, Monkkonen H, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008; 14: 4658-4666.
29. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I,. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008; 100: 1167-1178.
30. Ural AU, Avcu F, Candir M, Guden M, Ozcan MA,. In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells. Breast Cancer Res. 2006; 8: R52.
31. Vogt U, Bielawski KP, Bosse U, Schlotter CM,. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5- fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep. 2004; 12: 1109-1114.
32. Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A,. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol. 2003; 26: S92-S97.
33. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I,. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs. 2005; 16: 845-854.
34. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I,. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer. 2010; 126: 522-532.
35. Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003; 9: 295-306.
36. Daubine F, Le Gall C, Gasser J, Green J, Clezardin P,. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007; 99: 322-330.
37. Padalecki SS, Carreon M, Grubbs B, Cui Y, Guise TA,. Androgen deprivation enhances bone loss and prostate cancer metastases to bone: prevention by zoledronic acid [abstract]. Oncology. 2003; 17 (suppl 3): 32.
38. Peyruchaud O, Winding B, Pecheur I, Serre C-M, Delmas P, Clezardin P,. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res. 2001; 16: 2027-2034.
39. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T,. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004; 10: 4559-4567.
40. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357: 1799-1809.
41. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002; 62: 6538-6544.
42. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002; 8: 1080-1084.
43. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007; 13: 4482-4486.
44. Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005; 25: 144-151.
45. Traina TA,. Bevacizumab in the treatment of metastatic breast cancer. Oncology (Williston Park). 2009; 23: 327-332.
46. Girardi M,. Immunosurveillance and immunoregulation by γδ T cells. J Invest Dermatol. 2006; 126: 25-31.
47. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony H-P, Wilhelm M,. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000; 96: 384-392.
48. Sato K, Kimura S, Segawa H, et al. Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer. 2005; 116: 94-99.
49. Santini D, Martini F, Fratto ME, et al. In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients. Cancer Immunol Immunother. 2009; 58: 31-38.
50. Chambers AF, Groom AC, MacDonald IC,. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2: 563-572.
51. Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow [poster]. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Texas. Abstract 510.
52. Lin AY, Park JW, Scott J, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [poster]. Poster presented at: 44th Annual Meeting of the American Society of Clinical Oncology; May 30-June 3, 2008; Chicago, Illinois. Abstract 559.
53. Rack BK, Jueckstock J, Genss E-M, et al. Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer [abstract]. Breast Cancer Res Treat. 2007; 106 (suppl 1): S40. Abstract 511.
54. Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [poster]. Poster presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14 2008; San Antonio, Texas. Abstract 2048.
55. Aft R, Chavez-MacGregor M, Trinkaus K, Naughton M, Weilbaecher K,. Effect of zoledronic acid on bone loss in women undergoing chemotherapy for breast cancer [abstract]. Breast Cancer Res Treat. 2007; 106 (suppl 1): S38. Abstract 505.
56. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008; 113: 193-201.
57. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 1458-1468.
58. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R,. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007; 110: 1860-1867.
59. Saad F, Lipton A,. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int. 2005; 96: 964-969.
60. Saad F,. Bisphosphonates can prevent skeletal complications of malignant bone disease from prostate cancer and renal cell carcinoma. Eur Urol. 2007; 6 (suppl): 683-688.
61. Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L,. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol. 2005; 22: 195-201.
62. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008; 113: 1588-1595.
63. Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J,. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol. 2007; 24: 227-230.
64. Zaghloul MS, Boutrus R, El-Hosieny H, A-Kader Y, El-Attar I, Nazmy M,. A controlled prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients [abstract]. J Clin Oncol. 2008; 26 (suppl): 257s. Abstract 5033.
65. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer. 2009; 125: 1705-1709.
66. Mitsiades CS, Bogdanos J, Karamanolakis D, Milathianakis C, Dimopoulos T, Koutsilieris M,. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res. 2006; 26: 3693-3700.
67. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005; 23: 4925-4935.
68. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005; 97: 59-69.
69. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 2008; 3: 228-236.
70. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE,. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007; 12: 1035-1043.
71. Coleman RE, Cook RJ, Saad F, et al. Meta-analysis of effects of zoledronic acid on survival in patients with metastatic bone disease and high bone turnover [poster]. Poser presented at: VII International Meeting on Cancer Induced Bone Disease; June 29-July 2, 2008; Edinburgh, Scotland. Poster P81.
72. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 2008; 19: 1407-1416.
73. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007; 25: 829-836.
74. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009; 9: 77-85.
75. Bundred N, Campbell I, Coleman R, et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study) [abstract]. Eur J Cancer. 2006; 4 (suppl): 48. Abstract 12.
76. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008; 112: 1001-1010.
77. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007; 25: 820-828.
78. Schenk N, Lombart A, Frassoladti A, et al. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let) [abstract]. Eur J Cancer. 2007; 5 (suppl 5): 186-187. Abstract 2008.
79. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008; 9: 840-849.
80. Eidtmann H, Bundred N, de Boer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow-up of ZO-FAST [oral presentation]. Presented orally at: 32nd Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, Texas. Abstract 44.
81. Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008; 13: 503-514. (Pubitemid 351872868)
82. Llombart A, Frassoldati A, Paija O, et al. Effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST [abstract]. Paper presented at: American Society of Clinical Oncology 2009 Breast Cancer Symposium; October 8-10, 2009; San Francisco, California. Abstract 213.
83. Coleman R, Bundred N, de Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST [poster]. Poster presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, Texas. Abstract 4082.
84. University of Sheffield. Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer. ClinicalTrials.gov Identifier, NCT00072020. Accessed December 14, 2009.
85. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] [serial online]. Breast Cancer Res. 2006; 8: R13.
86. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002; 20: 3219-3224.
87. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998; 339: 357-363.
88. Saarto T, Blomqvist C, Virkkunen P, Elomaa I,. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001; 19: 10-17.
89. Ha TC, Li H,. Meta-analysis of clodronate and breast cancer survival. Br J Cancer. 2007; 96: 1796-1801.
90. German Breast Group. Study in Elderly Patients With Early Breast Cancer (ICE). ClinicalTrials.gov Identifier, NCT00196859. Accessed December 14, 2009.
91. German Breast Group. A Study to Compare ETC vs EC-TX and Ibandronate vs Observation in Patients With Node-Positive Primary Breast Cancer (GAIN). ClinicalTrials.gov Identifier, NCT00196872. Accessed December 14, 2009.
92. Paterson AH,. The role of bisphosphonates in early breast cancer. Oncologist. 2006; 11 (suppl 1): 13-19.
93. Sheffield Teaching Hospitals NHS Foundation Trust. Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-Operative Chemotherapy in Breast Cancer (ANZAC). ClinicalTrials.gov Identifier, NCT00525759. Accessed December 14, 2009.
94. German Breast Group. Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy (NATAN). ClinicalTrials.gov Identifier, NCT00512993. Accessed December 14, 2009.
95. The SUCCESS Study Group. [News from the SUCCESS study]. Accessed December 14, 2009.
96. Southwest Oncology Group. Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery For Stage I, Stage II, or Stage III Breast Cancer. ClinicalTrials.gov Identifier, NCT00127205. Accessed December 14, 2009.
97. European Association of Urology. Effectiveness of Zometa Treatment for the Prevention of Bone Metastases in High Risk Prostate Cancer Patients: A Randomised, Open-Label, Multicentre Study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). ISRCTN Register no. 66626762. Accessed December 14, 2009.
98. Trans-Tasman Radiation Oncology Group. RADAR Trial - Randomized Androgen Deprivation and Radiotherapy. ClinicalTrials.gov Identifier, NCT00193856. Accessed December 14, 2009.
99. Medical Research Council. Androgen Suppression Alone or Combined With Zoledronate, Docetaxel, Prednisolone, and/or Celecoxib in Treating Patients With Locally Advanced or Metastatic Prostate Cancer. ClinicalTrials.gov Identifier, NCT00268476. Accessed December 14, 2009.
100. James ND, Sydes MR, Clarke NW, et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int. 2009; 103: 464-469.
101. Novartis. A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-Small Cell Lung Cancer. ClinicalTrials.gov Identifier, NCT00172042. Accessed December 14, 2009.
102. Gleneagles Hospital. Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma (dtZ). ClinicalTrials. gov Identifier, NCT00263484. Accessed December 14, 2009.
103. Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR,. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009; 10: 872-876.